Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on CYTOKINETICS, INC.
04/28 CYTOKINETICS INC : Results of Operations and Financial Condition, Financial Stat..
04/28 Cytokinetics, Inc. Reports First Quarter 2016 Financial Results
04/25CYTOKINETICS, INC. : quaterly earnings release
04/14 CYTOKINETICS : to Announce First Quarter Results on April 28, 2016
04/14 Cytokinetics to Announce First Quarter Results on April 28, 2016
04/05 CYTOKINETICS : to Present at the 15th Annual Needham Healthcare Conference
04/05 Cytokinetics to Present at the 15th Annual Needham Healthcare Conference
04/05 CYTOKINETICS : Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil i..
04/04 CYTOKINETICS : Other Events (form 8-K)
04/04 Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil ..
Advertisement
Income Statement Evolution
More Financials